Allergen immunotherapy: Where is it now?

Journal of Allergy and Clinical Immunology

Volumn 119, Issue 4, 2007, Pages 769-777

  Nelson, Harold S ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

asthma; Immunotherapy; rhinitis; SCIT; SLIT; subcutaneous; sublingual

Indexed keywords

ALLERGEN; ALTERNARIA EXTRACT; BIRCH POLLEN EXTRACT; CAT DANDER EXTRACT; DNA; DOG DANDER EXTRACT; HOUSE DUST ALLERGEN; HYBRID PROTEIN; OMALIZUMAB; PLACEBO; PLANT EXTRACT; POLLEN EXTRACT; RAGWEED ANTIGEN; STEROID; TIMOTHY EXTRACT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALLERGENICITY; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALLERGY; ATOPIC DERMATITIS; BASOPHIL; CLINICAL TRIAL; DISEASE COURSE; DNA SEQUENCE; FOOD ALLERGY; GASTROINTESTINAL SYMPTOM; GRASS ALLERGY; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; IN VIVO STUDY; MAST CELL; MOUTH EDEMA; MUTAGENESIS; ORAL PRURITUS; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; SWELLING; URTICARIA; VOMITING;

ALLERGENS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; INJECTIONS, SUBCUTANEOUS;

EID: 34047179902     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2007.01.036     Document Type: Review

References (93)

1. Ross R.N., Nelson H.S., and Finegold I. Effectiveness of specific immunotherapy in the treatment of hymenoptera venom hypersensitivity: a meta-analysis. Clin Ther 22 (2000) 351-358
2. Ross R.N., Nelson H.S., and Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized prospective, single- or double-blind, placebo-controlled studies. Clin Ther 22 (2000) 342-350
3. Abramson M.J., Puy R.M., and Weiner J.M. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 4 (2003) CD001186
4. Grier T.J., Hazelhurst D.M., Duncan E.A., West T.K., and Esch R.E. Major allergen measurements: sources of variability, validation, quality assurance, and utility for laboratories, manufacturers and clinics. Allergy Asthma Proc 29 (2002) 125-131
5. Creticos P.S., Adkinson N.F., Sobotka A., Proud D., Meier H.L., Naclerio R.M., et al. Nasal challenge with ragweed pollen in hay fever patients: effect of immunotherapy. J Clin Invest 76 (1985) 2247-2253
6. Furin M.J., Norman P.S., Creticos P.S., Proud D., Sobotka A., and Lichtenstein L.M. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol 88 (1991) 27-32
7. Creticos P.S., Marsh D.G., Proud D., Sobotka A., Adkinson N.F., and Friedhoff L. Responses to ragweed-pollen nasal challenge before and after immunotherapy. J Allergy Clin Immunol 84 (1989) 197-205
8. Frew A.J., Powell R.J., Corrigan C.J., and Durham S.R. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 117 (2006) 319-328
9. Varney V.A., Edwards J., Tabbah K., Brewster H., Mavroleon G., and Frew A.J. Clinical efficacy of specific immunotherapy to cat dander: a double-blind, placebo-controlled trial. Clin Exp Allergy 27 (1997) 860-867
10. Khinchi M.S., Poulsen L.K., Carat F., Andre C., Hansen A.B., and Malling H.J. Clinical efficacy of sublingual and subcutaneous Birch pollen allergen specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 59 (2004) 45-53
11. Rak S., Heinrich C., and Schevnius A. Comparison of nasal immunohistology in patients with seasonal rhinoconjunctivitis treated with topical steroids or specific allergen immunotherapy. Allergy 60 (2005) 643-649
12. Olaquibel J.M., Tabar A.I., Garcia B.E., Martin S., and Rico P. Long-term immunotherapy with an optimal maintenance dose of a standardized Dermatophagoides pteronyssinus extract in asthmatic patients. J Investig Allergol Clin Immunol 9 (1999) 110-116
13. Ewan P.W., Alexander M.M., Snape C., Ind P.W., Agrell B., and Dreborg S. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite. Clin Allergy 18 (1988) 501-508
14. Haugaard L., Dahl R., and Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 91 (1993) 709-722
15. Olsen O.T., Larsen K.R., Jacobsen L., and Svendsen U.G. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 52 (1997) 853-859
16. Alvarez-Cuesta E., Cuesta-Herranz J., Puyana-Ruiz J., Cuesta-Herranz C., and Blanco-Quiros A. Monoclonal antibody-standardized cat immunotherapy: risk benefit effects from a double-blind study. J Allergy Clin Immunol 93 (1994) 556-566
17. Hedlin J.G., Lonnevig V., Heilbron H., Lilja G., Norrlind K., and Pegelow K. Immunotherapy with cat- and dog-dander extracts, V: effects of 3 years of treatment. J Allergy Clin Immunol 87 (1991) 955-964
18. Ewbank P.A., Murray J., Sanders K., Curran-Everett D., Dreskin S., and Nelson H.S. A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. J Allergy Clin Immunol 111 (2003) 155-161
19. Nanda A., O'Connor M., Anand M., Dreskin S.C., Zhang L., Hines B., et al. Dose dependence and time course of the immunologic response to administration of standardized cal allergen extract. J Allergy Clin Immunol 114 (2004) 1339-1344
20. Lent A., Harbeck R., Strand M., Sills M., Schmidt K., Efaw B., et al. Immunological response to administration of standardized dog allergen extract at differing doses. J Allergy Clin Immunol 118 (2006) 1249-1256
21. Horst M., Hejjaoui A., Horst V., Michel F.-B., and Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 85 (1990) 460-472
22. Lavins B.J., Dolen W.K., Nelson H.S., and Weber R.W. Use of standardized and conventional allergen extracts in prick skin testing. J Allergy Clin Immunol 89 (1992) 658-666
23. Patterson M.L., and Slater J.E. Characterization and comparison of commercially available German and American cockroach allergen extracts. Clin Exp Allergy 32 (2002) 721-727
24. Vailes L., Sridhara S., Cromwell O., Weber B., Breitenbach M., and Chapman M. Quantitation of the major fungal allergens, Alt a 1 and Asp f 1, in commercial_allergenic products. J Allergy Clin Immunol 107 (2001) 641-646
25. Lowell F.C., and Franklin W. A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N Engl J Med 273 (1965) 675-679
26. Norman P.S., and Lichtenstein L.M. The clinical and immunologic specificity of immunotherapy. J Allergy Clin Immunol 61 (1978) 370-377
27. Des Roches A., Paradis L., Menardo J.-L., Bouges S., Daures J.-P., and Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract, VI: specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 99 (1997) 450-453
28. Pajno G.B., Barberio G., De Luca F., Morabito L., and Parmiani S. Prevention of new sensitization in asthmatic children monosensitized to house dust mite by specific immunotherapy: a six-year, follow-up study. Clin Exp Allergy 31 (2001) 1392-1397
29. Purello-D'Ambrosio F., Gangemi S., Merendino R.A., Isola S., Puccinelli P., Parmiani S., et al. Prevention of new sensitization in monosensitized subjects submitted to specific immunotherapy or not: a retrospective study. Clin Exp Allergy 31 (2001) 1295-1302
30. Moller C., Dreborg S., Ferdousi H.A., Halken S., Host A., Jacobsen L., et al. Pollen immunotherapy reduces he development of asthma in children with seasonal rhinoconjunctivitis (the PAT Study). J Allergy Clin Immunol 109 (2002) 251-256
31. Niggemann B., Jacobsen L., Dreborg S., Ferdousi H.A., Halken S., Host A., et al. Five-year follow-up on the PAT study: specific immunotherapy and long term prevention of asthma in children. Allergy 61 (2006) 855-859
32. Valovirta E., Jacobsen L., Niggemann B., Dreborg S., Ferdousi H., Halken S., et al. A 3-year course of subcutaneous specific immunotherapy results in long-term prevention of asthma in children: ten-year follow-up on the PAT-Study. [abstract]. J Allergy Clin Immunol 117 (2006) 721
33. Ebner C., Kraft D., and Ebner H. Booster immunotherapy (IT). Allergy 49 (1994) 38-42
34. Des Roches A., Paradis L., Knani J., Hejjaoui A., Dhivert H., Chanez P., et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract, V: duration of the efficacy of immunotherapy after its cessation. Allergy 51 (1996) 430-433
35. Durham S.R., Walker S.M., Varga E.-M., Jacobson M.R., O'Brien F., Noble W., et al. Long-term clinical efficacy of grass pollen immunotherapy. N Engl J Med 344 (1999) 468-475
36. Werfel T., Breuer K., Rueff F., Przybilla B., Worm M., Grewe M., et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 61 (2006) 202-205
37. Nelson H.S., Lahr J., Rule R., Bock A., and Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 99 (1997) 744-751
38. Bucher X., Pichler W.J., Dahinden C.A., and Helbling A. Effect of tree pollen specific subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut. Allergy 59 (2004) 1272-1276
39. Bolhaar S.T.H.P., Tiemessen M.M., Zuidmeer I., van Leeuwen A., Hoffmann-Sommergruber K., Bruijnzeel-Koomen C.A.F.M., et al. Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges. Clin Exp Allergy 34 (2004) 761-769
40. Asero R. How long does the effect of birch pollen injection SIT on apple allergy last?. Allergy 58 (2003) 435-438
41. Franklin W., and Lowell F.C. Comparison of two dosages of ragweed extract in the treatment of pollinosis. JAMA 201 (1967) 915-917
42. Johnstone D.E., and Crump L. Value of hyposensitization therapy for perennial bronchial asthma in children. Pediatrics 27 (1961) 39-44
43. Tankersley M.S., Butler K.K., Butler W.K., and Groetz D.W. Local reactions during allergen immunotherapy do not require dose adjustment. J Allergy Clin Immunol 100 (2000) 840-843
44. Lin MS, Tanner E, Lynn J, Friday GA Jr. Nonfatal systemic allergic reactions induced by skin testing and immunotherapy. Ann Allergy 1993;71:557-62.
45. Tinkelman D.G., Cole III W.O., and Tunno J. Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions. J Allergy Clin Immunol 95 (1995) 8-14
46. Reid M.J., Lockey R.F., Turkeltaub P.C., and Platts-Mills T.A.E. Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol 92 (1993) 6-15
47. Bernstein D.I., Wanner M., Borish L., and Liss G.M. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 113 (2004) 1129-1136
48. Sharkey P., and Portnoy J. Rush immunotherapy: experience with a one-day schedule. Ann Allergy Asthma Immunol 76 (1996) 175-180
49. Van Metre Jr. E., Adkinson Jr. N.F., Amodio F.J., Kagey-Sobotka A., Lichtenstein L.M., Mardiney Jr. M.R., et al. A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol 69 (1982) 181-193
50. Tabar A.I., Echechipia S., Garcia B.E., Olaguibel M.J., Lizaso M.T., Gomez B., et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol 116 (2005) 109-118
51. Salvaggio J., and Aukrust L. Mold-induced asthma. J Allergy Clin Immunol 68 (1981) 327-346
52. O'Hollaren M., Yunginger J.W., Offord K.P., Somers M.J., O'Connell E.J., Ballard D.J., et al. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. N Engl J Med 324 (1991) 759-763
53. Targonski P.V., Persky V.W., and Ramekrishnan V. Effect of environmental molds on risk of death from asthma during the pollen season. J Allergy Clin Immunol 95 (1995) 955-961
54. Dreborg S., Agrell B., Foucard T., Kjellman N.I., Koivikko A., and Nilsson S. A double-blind, multicenter immunotherapy trial in children using a purified and standardized Cladosporium herbarum preparation. Allergy 41 (1986) 131-140
55. Malling H.-J., Dreborg S., and Weeke B. Diagnosis and immunotherapy of mould allergy, V: clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy 41 (1986) 507-519
56. Vailes L., Sridhara S., Cromwell O., Weber B., Breitenbach M., and Chapman M. Quantification of the major fungal allergens, Alt a 1 and Asp f 1, in commercial allergenic products. J Allergy Clin Immunol 107 (2001) 641-646
57. Salvaggio J.E., Burge H.A., and Chapman J.A. Emerging concepts in mold allergy: what is the role of immunotherapy?. J Allergy Clin Immunol 92 (1993) 217-222
58. Nelson H.S. Use of standardized allergen extracts in allergen immunotherapy. J Allergy Clin Immunol 106 (2000) 41-45
59. Esch R.E. Role of proteases on the stability of allergenic extracts. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 85 (1992) 171-177
60. Nelson H.S., Ikle D., and Buchmeier A. Studies of allergen extract stability: the effects of dilution and mixing. J Allergy Clin Immunol 91 (1996) 382-388
61. Drachenberg K.J., Wheeler A.W., Stuebner P., and Horak F. A well tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 56 (2001) 498-505
62. Basomba A., Tabar A.I., de Roas D.H.R., Garcia B.E., Alamar R., Olaguibel J.M., et al. Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: a randomized, double-blind placebo-controlled trial in asthmatic patients. J Allergy Clin Immunol 109 (2002) 943-948
63. Casale T.B., Busse W.W., Kline J.N., Ballas Z.K., Moss M.H., Townley R.G., et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117 (2006) 134-140
64. Canonica G.W., and Passalacqua G. Non-injection routes for immunotherapy. J Allergy Clin Immunol 111 (2003) 437-448
65. Wilson D.R., Torres-Lima M., and Durham S.R. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60 (2005) 4-12
66. Penagos M., Compalati E., Tarantini F., Baena-Cagnani R., Huerta J., Passalacqua G., et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 97 (2006) 141-148
67. Calamita Z., Saconato H., Pela A.B., and Atallah A.N. Efficacy of sublingual immunotherapy in asthmatics: systematic review of randomized clinical trials using the Cochrane Collaboration method. Allergy 61 (2006) 1162-1172
68. Cox L.S., Linnemann D.L., Nolte H., Weldon D., Finegold I., and Nelson H.S. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 117 (2006) 1021-1035
69. Dahl R., Kapp A., Colombo G., de Monchy J.G.R., Rak S., Emminger W., et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 118 (2006) 434-440
70. Gidaro G.B., Marcucci F., Sensi L., Incorvaia C., Frati F., and Ciprandi G. The safety of sublingual-swallow immune therapy: an analysis of published studies. Clin Exp Allergy 35 (2005) 565-571
71. Dunsky E.H., Goldstein M.F., Dvorin D.J., and Belecanach G.A. Anaphylaxis to sublingual immunotherapy. Allergy 61 (2006) 1235
72. Mempel M., Rakoski J., Ring J., and Ollert M. Severe anaphylaxis to kiwi fruit: Immunologic changes related to successful sublingual allergen immunotherapy. J Allergy Clin Immunol 111 (2003) 1406-1409
73. Enrique E., Pineda F., Malck T., Bartra J., Basagana M., Tella R., et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol 116 (2005) 1073-1079
74. Pajno G.B., Vita D., Caminiti L., Arrigo T., Lombardo F., and Barberio G. House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. [abstract]. J Allergy Clin Immunol 117 (2006) S233
75. Bordignon V., and Burastero S.E. Multiple daily administrations of low-dose sublingual immunotherapy in allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol 97 (2006) 158-163
76. Ippoliti F., de Santis W., Volteraini A., Lenti L., Canitano N., Lucarelli S., et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 13 (2003) 216-221
77. Marogna M., Spadolini I., Massolo A., Canonica G.W., and Passalacqua G. Clinical, functional and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J Allergy Clin Immunol 115 (2005) 1184-1188
78. Di Rienzo V., Marcucci F., Puccinelli P., Parmiani S., Frati F., Sensi L., et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 33 (2003) 206-210
79. Novembre E., Galli E., Landi F., Caffarelli C., Pifferi M., De Marco E., et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 114 (2004) 851-857
80. Durham S.R., Yang W.H., Pedersen M.R., Johansen N., and Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 117 (2006) 802-809
81. Marcucci F., Sensi L., Di Cara G., Incorvaia C., and Frati F. Dose dependence of immunological response to sublingual immunotherapy. Allergy 60 (2005) 952-956
82. Khinchi M.S., Poulsen L.K., Carat F., Andre C., Hansen A.B., and Maling H.-J. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 59 (2004) 45-53
83. Torres Lima M., Wilson D., Pitki L., Roberts A., Nouri-Aria K., Jacobson M., et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 32 (2002) 507-514
84. Passalacqua G., Musarra A., Pecora S., Amoroso S., Antonicelli L., Cadario G., et al. Quantitative assessment of the compliance with a once-daily sublingual immunotherapy regimen in real life (EASY Project evaluation of A novel SLIT formulation during a Year). J Allergy Clin Immunol 117 (2005) 946-948
85. Pajno G.B., Vita D.C., Caminiti L., Arrigo T., Lombardo F., Incorvaia C., et al. Children's compliance with allergen immunotherapy according to administration routes. J Allergy Clin Immunol 116 (2005) 1380-1381
86. Corrigan C.J., Kettner J., Doemer C., Cromwell O., and Narkus A. Efficacy and safety of preseasonally-specific immunotherapy with an aluminum-adsorbed six-grass pollen allergoid. Allergy 60 (2005) 801-807
87. Jutel M., Jaeger L., Suck R., Meyer H., Fiebig H., and Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 116 (2005) 608-613
88. Niederberger V., Horak F., Vrtala S., Spitzauer S., Krauth M.-T., Valent P., et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 101 (2004) 14677-14682
89. Alexander C., Tarzi M., Larche M., and Kay A.B. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 60 (2005) 1269-1274
90. Creticos P.S., Schroeder J.T., Hamilton R.G., Baker-Whae S.L., Khattignaong A.P., Lindblad R., et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 355 (2006) 1445-1455
91. Busse W., Gross G., Korenblat P., Nayak A., Tarpay M., Levitt D., et al. Phase 2/3 study of the novel vaccine Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate AIC in ragweed-allergic adults. [abstract]. J Allergy Clin Immunol 117 (2006) S88-S89
92. Zhu D., Kepley C.I., Zhang K., Terada T., Yamada T., and Saxon A. A chimeric human-cat fusion protein blocks cat-induced allergy. Nature Med 11 (2005) 446-449
93. Terada T., Zhang K., Belperio J., Londhe V., and Saxon A. A chimeric human-cat Fcγ-Fel d 1 fusion protein inhibits systemic, pulmonary, and cutaneous allergic reactivity to intratracheal challenge in mice sensitized to Fel d 1, the major cat allergen. Clin Immunol 120 (2006) 45-56